findmyKOL
Clinical trialNCT00336791CompletedPhase 3Interventional

Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer

SponsorM.D. Anderson Cancer CenterEnrollment273Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Mexico
  • Centro Medico Nacional de Occidente

    Guadalajara, Mexico

Peru
  • Instituto Nacional de Enfermedades Neoplasicas

    Lima, Peru

Spain
  • Grupo Español de Investigacion En Cancer de Mama

    Madrid, Spain

United States
  • Ut Md Anderson Cancer Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Sept 2003
Primary completion
31 Aug 2007
Completion
30 Sept 2010
Last update posted
14 Feb 2012
Registered enrollment
273
Registry id
NCT00336791

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.